Full Press Release Details
Inogen Announces First Quarter 2022 Financial Results
- Q1 2022 Total Revenue of $80.4 million -
Goleta, California, May 5, 2022 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three months ended March 31, 2022.
First Quarter 2022 Highlights
"We are pleased with our performance for the first quarter of 2022. In spite of the current macro headwinds, we continue to effectively address higher costs and supply chain challenges," said Inogen's President and Chief Executive Officer, Nabil Shabshab. "We have been nimble and decisive in our efforts to strategically manage inventory and meet most of the customer demand. As part of our focus to mitigate supply related cost inflation, we have recently implemented an additional price increase in our domestic direct-to-consumer channel beginning in March 2022 in addition to the price increase that went into effect September 2021. Additionally, we have completed the submission for the EU MDR Generic Device Group pertaining to our POCs in March 2022 and are supplying product ahead of the MDD certificate expiry to meet most of the
demand in Europe. We are continuing our investment in the business, strengthening our commercial, clinical and research and development capabilities to position our company for long-term, sustainable growth and profitability in the years to come."
First Quarter 2022 Financial Results
In the first quarter of 2022, the Company reported a net loss of $14.2 million and loss per diluted share of $0.62. On an adjusted basis, the Company reported a net loss of $8.8 million, Adjusted EBITDA loss of $5.0 million, and loss per diluted share of $0.39 (see accompanying table for reconciliation of GAAP and non-GAAP measures). Current quarter financial results reflect lower revenue, higher supply chain costs, and planned investments in sales and marketing and research and development.
Total revenue for the three months ended March 31, 2022 decreased 7.5% to $80.4 million from $86.9 million in the same period in 2021, primarily driven by supply chain constraints that limited production capacity and resulted in lower sales in the domestic business-to-business channel. Total revenue in the first quarter of 2022 was up 5.2% sequentially compared to the fourth quarter of 2021.
Domestic direct-to-consumer sales increased 12.2% to $34.4 million in the first quarter of 2022 from $30.6 million in the first quarter of 2021 while domestic business-to-business sales in the first quarter of 2022 declined 83.4% to $5.1 million compared to $30.7 million in the first quarter of 2021 due to supply constraints and strategic sales channel optimization decisions.
International business-to-business sales in the first quarter of 2022 of $27.9 million increased 77.7% (or 86.8% on a constant currency basis) driven by a strategic focus on existing demand ahead of the EU MDR certificate expiry in parallel to the ongoing regulatory filings.
Rental revenue in the first quarter of 2022 increased 31.8% to $13.0 million from $9.9 million in the same period in 2021, primarily due to increased patients on service and higher Medicare reimbursement rates due to the removal of the budget neutrality provision effective April 1, 2021 and inflation adjustment effective January 1, 2022.
Total gross margin was 43.5% in the first quarter of 2022 versus 45.9% in the comparative period in 2021. The 240 basis points decline was driven primarily by higher cost of materials associated with higher prices paid for semiconductor chips on the open market and lower labor and overhead absorption due to the temporary manufacturing shutdown in early 2022, partially offset by higher average selling prices.
Total operating expense increased to $48.6 million in the first quarter of 2022 versus $42.0 million in the first quarter of 2021, primarily due to increased personnel-related expense, one-time recruiting and severance costs, consulting expense, product development costs, and a non-cash increase in the change in fair value of the New Aera earnout liability versus the comparative period. Research and development expense increased to $5.4 million in the first quarter of 2022, compared to $4.0 million in the first quarter of 2021. Sales and marketing expense increased to $28.0 million in the first quarter of 2022 versus $25.5 million in the comparative period of 2021. General and administrative expense increased to $15.2 million in the first quarter of 2022 versus
$12.5 million in the first quarter of 2021. The increased spend is directly tied to the strategic investment required to position the Company for long-term, sustainable growth.
Financial Outlook for 2022
As previously disclosed, Inogen is not providing detailed financial guidance for full year 2022. Given the ongoing uncertainty related to the COVID-19 pandemic, supply chain disruptions, including the new complexities brought on by the war in Ukraine and the COVID-19 lockdown in China potentially impacting the second half of the year, Inogen will not be providing full year revenue guidance for 2022. The Company expects total revenue for the second quarter of 2022 to improve sequentially and to be in line with the same period in 2021.
The Company continues to incur higher material costs associated with open-market purchases of semiconductor chips used in its POC motherboards and batteries for the second quarter of 2022, as compared to prior year, consistent with our expectations. The Company expects gross margin percentage for the second quarter of 2022 to be in line with the first quarter of 2022, as higher selling prices are offset by continued cost pressure.
Inogen continues to make significant investments in clinical research, research and development, commercial operations and in building the necessary infrastructure and capabilities to support future durable revenue growth and margin expansion. For the second quarter and full year of 2022, the Company expects losses in Adjusted EBITDA and earnings per diluted share resulting from continued investment in the business.
Individuals interested in listening to the conference call today at 2:00pm PT/5:00pm ET may do so by dialing (877) 841-3961 for domestic callers or (201) 689-8589 for international callers. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/.
A replay of the call will be available beginning May 5, 2022 at 4:00pm PT/7:00pm ET through May 19, 2022. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Access Code: 13727825. The webcast will also be available on Inogen's website for one year following the completion of the call.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
Inogen is a medical technology company offering innovative respiratory products for use in the homecare setting. The Company primarily develop, manufacture and market innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the Company's expectations related to its financial results for the second quarter and full-year 2022, including revenue growth rates, cost of goods sold, operating loss, net loss, Adjusted EBITDA and operating expense; expectations with respect to the Company's supply chain, including the availability of semiconductor chips used in its batteries and POCs; demand for the Company's products in its various business channels; expectations regarding the Company's initiatives to drive productivity and sales; the Company's planned investments in clinical research and R expectations regarding the Company's prospects for long-term, sustainable growth and profitability; expectations related to the Company's prescriber sales organization; and expectations related to the Company's EU MDR filings. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks arising from the possibility that Inogen will not realize anticipated revenue; risks related to the Company's supply chain and limited availability of semiconductor chips used in its batteries and POCs, the risk of further slowdowns or temporarily halts of production, or cost inflation for such components; the impact of changes in reimbursement rates and reimbursement and regulatory policies; the possible loss of key employees, customers, or suppliers; expenses and costs will exceed Inogen's expectations; intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. In addition, Inogen's business is subject to numerous additional risks and uncertainties and information on these and additional risks, uncertainties, and other information affecting Inogen's business operating results are contained in its Annual Report on Form 10-K for the period ended December 31, 2021, and in its other filings with the Securities and Exchange Commission. Additional information will also be set forth in Inogen's Quarterly Report on Form 10-Q for the period ended March 31, 2022, to be filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
Use of Non-GAAP Financial Measures
Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three months ended March 31, 2022. Management believes that non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of Inogen's core operating results. Management uses non-GAAP measures to compare Inogen's performance relative to forecasts and strategic plans, to benchmark Inogen's performance externally against competitors, and for certain compensation decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Inogen's operating results as reported under U.S. GAAP. Inogen encourages investors to carefully consider its results under U.S. GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between U.S. GAAP and non-GAAP results are presented in the accompanying tables of this release. For future periods,
Inogen is unable to provide a reconciliation of non-GAAP measures without unreasonable effort as a result of the uncertainty regarding, and the potential variability of, the amounts of interest income, interest expense, depreciation and amortization, stock-based compensation, provision for income taxes, and certain other infrequently occurring items, such as acquisition-related costs, that may be incurred in the future.
Investor and Media Contacts
Bryan Locke, Mike DeGraff, Gabriella Coffey
--Financial Tables Follow -
| Consolidated Balance Sheets | ||||||||
| (unaudited) | ||||||||
| (amounts in thousands) | ||||||||
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 213,399 | $ | 235,524 | ||||
| Marketable securities | 9,989 | 9,989 | ||||||
| Accounts receivable, net | 33,983 | 24,452 | ||||||
| Inventories, net | 34,078 | 31,873 | ||||||
| Income tax receivable | 1,435 | 1,343 | ||||||
| Prepaid expenses and other current assets | 25,238 | 26,005 | ||||||
| Total current assets | 318,122 | 329,186 | ||||||
| Property and equipment, net | 39,329 | 38,926 | ||||||
| Goodwill | 32,934 | 32,979 | ||||||
| Intangible assets, net | 58,000 | 60,147 | ||||||
| Operating lease right-of-use asset | 24,080 | 24,912 | ||||||
| Other assets | 2,151 | 3,363 | ||||||
| Total assets | $ | 474,616 | $ | 489,513 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 32,375 | $ | 25,689 | ||||
| Accrued payroll | 8,839 | 17,307 | ||||||
| Warranty reserve - current | 6,519 | 6,480 | ||||||
| Operating lease liability - current | 3,401 | 3,393 | ||||||
| Deferred revenue - current | 8,689 | 8,568 | ||||||
| Income tax payable | - | 75 | ||||||
| Total current liabilities | 59,823 | 61,512 | ||||||
| Warranty reserve - noncurrent | 6,574 | 7,246 | ||||||
| Operating lease liability - noncurrent | 22,409 | 23,281 | ||||||
| Earnout liability - noncurrent | 16,016 | 15,386 | ||||||
| Deferred revenue - noncurrent | 11,509 | 11,861 | ||||||
| Total liabilities | 116,331 | 119,286 | ||||||
| Stockholders' equity | ||||||||
| Common stock | 23 | 23 | ||||||
| Additional paid-in capital | 302,020 | 299,463 | ||||||
| Retained earnings | 55,058 | 69,272 | ||||||
| Accumulated other comprehensive income | 1,184 | 1,469 | ||||||
| Total stockholders' equity | 358,285 | 370,227 | ||||||
| Total liabilities and stockholders' equity | $ | 474,616 | $ | 489,513 |
| Consolidated Statements of Comprehensive Loss | |||||||||
| (unaudited) | |||||||||
| (amounts in thousands, except share and per share amounts) | |||||||||
| Three months ended | |||||||||
| March 31, | |||||||||
| 2022 | 2021 | ||||||||
| Revenue | |||||||||
| Sales revenue | $ | 67,402 | $ | 77,081 | |||||
| Rental revenue | 12,983 | 9,851 | |||||||
| Total revenue | 80,385 | 86,932 | |||||||
| Cost of revenue | |||||||||
| Cost of sales revenue | 39,500 | 42,635 | |||||||
| Cost of rental revenue, including depreciation of $2,638 and $1,888, respectively | 5,879 | 4,424 | |||||||
| Total cost of revenue | 45,379 | 47,059 | |||||||
| Gross profit | 35,006 | 39,873 | |||||||
| Operating expense | |||||||||
| Research and development | 5,364 | 4,015 | |||||||
| Sales and marketing | 28,039 | 25,491 | |||||||
| General and administrative | 15,189 | 12,499 | |||||||
| Total operating expense | 48,592 | 42,005 | |||||||
| Loss from operations | (13,586 | ) | (2,132 | ) | |||||
| Other income (expense) | |||||||||
| Interest income | 29 | 57 | |||||||
| Other income (expense) | (433 | ) | (310 | ) | |||||
| Total other expense, net | (404 | ) | (253 | ) | |||||
| Loss before provision (benefit) for income taxes | (13,990 | ) | (2,385 | ) | |||||
| Provision (benefit) for income taxes | 224 | (1,653 | ) | ||||||
| Net loss | $ | (14,214 | ) | $ | (732 | ) | |||
| Other comprehensive income (loss), net of tax | |||||||||
| Change in foreign currency translation adjustment | (203 | ) | (457 | ) | |||||
| Change in net unrealized gains (losses) on foreign currency hedging | (528 | ) | 1,144 | ||||||
| Less: reclassification adjustment for net (gains) losses included in net income | 454 | (241 | ) | ||||||
| Total net change in unrealized gains (losses) on foreign currency hedging | (74 | ) | 903 | ||||||
| Change in net unrealized gains (losses) on marketable securities | (8 | ) | 4 | ||||||
| Total other comprehensive income, net of tax | (285 | ) | 450 | ||||||
| Comprehensive loss | $ | (14,499 | ) | $ | (282 | ) | |||
| Basic net loss per share attributable to common stockholders (1) | $ | (0.62 | ) | $ | (0.03 | ) | |||
| Diluted net loss per share attributable to common stockholders (1) | $ | (0.62 | ) | $ | (0.03 | ) | |||
| Weighted-average number of shares used in calculating net loss per share attributable to common stockholders: | |||||||||
| Basic common shares | 22,754,421 | 22,181,394 | |||||||
| Diluted common shares | 22,754,421 | 22,181,394 |
| Supplemental Financial Information | |||||||||
| (unaudited) | |||||||||
| (in thousands, except units and patients) | |||||||||
| Three months ended | |||||||||
| March 31, | |||||||||
| 2022 | 2021 | ||||||||
| Revenue by region and category | |||||||||
| Business-to-business domestic sales | $ | 5,101 | $ | 30,743 | |||||
| Business-to-business international sales | 27,941 | 15,720 | |||||||
| Direct-to-consumer domestic sales | 34,360 | 30,618 | |||||||
| Direct-to-consumer domestic rentals | 12,983 | 9,851 | |||||||
| Total revenue | $ | 80,385 | $ | 86,932 | |||||
| Additional financial measures | |||||||||
| Units sold | 30,400 | 49,400 | |||||||
| Net rental patients as of period-end | 43,200 | 34,700 |
| Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures | |||||||||
| (unaudited) | |||||||||
| (in thousands) | |||||||||
| Three months ended | |||||||||
| March 31, | |||||||||
| Non-GAAP EBITDA and Adjusted EBITDA | 2022 | 2021 | |||||||
| Net loss (GAAP) | $ | (14,214 | ) | $ | (732 | ) | |||
| Non-GAAP adjustments: | |||||||||
| Interest income | (29 | ) | (57 | ) | |||||
| Provision (benefit) for income taxes | 224 | (1,653 | ) | ||||||
| Depreciation and amortization | 5,760 | 5,098 | |||||||
| EBITDA (non-GAAP) | (8,259 | ) | 2,656 | ||||||
| Stock-based compensation | 2,665 | 2,516 | |||||||
| Change in fair value of earnout liability | 630 | 265 | |||||||
| Adjusted EBITDA (non-GAAP) | $ | (4,964 | ) | $ | 5,437 |
| Three months ended March 31, | ||||||||||||||||
| Net Income (Loss) | Diluted EPS | |||||||||||||||
| Non-GAAP Net Income (Loss) and Diluted EPS | 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Financial Results (GAAP) | $ | (14,214 | ) | $ | (732 | ) | $ | (0.62 | ) | $ | (0.03 | ) | ||||
| Non-GAAP adjustments: | ||||||||||||||||
| Amortization of intangibles | 2,147 | 2,264 | ||||||||||||||
| Stock-based compensation | 2,665 | 2,516 | ||||||||||||||
| Change in fair value of earnout liability | 630 | 265 | ||||||||||||||
| Income tax impact of adjustments (1) | 87 | (1,211 | ) | |||||||||||||
| Adjusted | $ | (8,685 | ) | $ | 3,102 | $ | (0.38 | ) | $ | 0.14 |
| Three months ended | |||||||||
| March 31, 2022 | |||||||||
| Non-GAAP international constant currency revenue | (using 2021 FX rates) | March 31, 2021 | |||||||
| International revenues (GAAP) | $ | 27,941 | $ | 15,720 | |||||
| Foreign exchange impact | 1,424 | - | |||||||
| International constant currency revenues (non-GAAP) | $ | 29,365 | $ | 15,720 | |||||
| International revenue growth (GAAP) | 77.7 | % | |||||||
| International constant currency revenue growth (non-GAAP) | 86.8 | % |